In July 2021, MorphoSys acquired Constellation Pharmaceuticals. This transformational acquisition bolstered MorphoSys’ position as a leader in hematology and oncology and marked the beginning of an important next chapter in the company's history. MorphoSys’ mission is more life for people with cancer. As a global commercial-stage biopharmaceutical company, MorphoSys uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. Read more about the acquisition here: https://www.morphosys.com/media-investors/media-center/morphosys-to-complete-transformational-acquisition-of-constellation Learn more about MorphoSys: www.MorphoSys.com
